Aurora Cannabis Inc.
Key Metrics
- Previous Close
- $3.91
- 52-Week Range
- $2.56 – $6.67
- Market Cap
- $241.21M
- P/E (TTM)
- —
- EPS (TTM)
- -0.66
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 0.64
- PEG Ratio
- —
- Return on Equity
- -9.40%
- Return on Assets
- -3.72%
- Gross Margin
- 44.18%
- Operating Margin
- -12.92%
- Profit Margin
- -38.25%
- Current Ratio
- 5.36
- Debt/Equity
- 0.04
- Total Debt
- $22.68M
- Free Cash Flow
- $-20.04M
- Revenue Growth
- -8.80%
- Earnings Growth
- —
- Enterprise Value
- $176.26M
Market Snapshot
About
Aurora Cannabis Inc. produces and distributes medical and consumer cannabis products across global markets. Headquartered in Edmonton, Alberta, the company operates licensed cultivation and production facilities in Canada and holds distribution agreements in over 20 countries. Aurora's product portfolio includes dried flower, oils, capsules, edibles, and vapes marketed under brands such as Aurora Drift, San Rafael '71, Daily Special, and Greybeard. The company serves both the Canadian recreational market and international medical cannabis markets, with significant operations in Europe through its European Medical Cannabis Partnership with Pedanios.
Aurora maintains approximately 1.5 million square feet of licensed production capacity across its Canadian facilities, including Aurora River and Aurora Sky. The company has undertaken significant restructuring initiatives in recent years, streamlining operations by closing underutilized facilities, reducing workforce, and focusing on profitability over revenue growth. Aurora sold its Danish cultivation subsidiary in 2023 as part of this rationalization strategy. The company has shifted toward higher-margin premium products and achieved positive adjusted EBITDA in several recent quarters.
As one of Canada's largest licensed cannabis producers by market capitalization, Aurora focuses on operational efficiency, brand development, and selective international expansion in medical markets. The company distributes products through provincial wholesalers in Canada and maintains research partnerships exploring cannabinoid applications in medical contexts.